UICC Virtual Dialogue on AMR & Cancer

The important role of R&D in addressing AMR for better cancer care

How can Research and Development (R&D) for novel antimicrobial medicines and a secure access pipeline effectively address AMR?

On 24th June, Dr. Lesley Ogilvie, the Hub Secretariat Director took part in the Virtual Dialogue: “Addressing Antimicrobial Resistance for Better Cancer Care – The Important Role of R&D”.

The session, organised by the Union for International Cancer Control (UICC):

・Provided information on various incentives currently being employed to improve the R&D pipeline for novel antimicrobials.
・Highlighted the need to develop a new approach to financing, coordinating, and collaborating on R&D for new antibiotics and diagnostics.
・Explored sustainable pathways for access.
・Highlighted the need for strengthened collaboration towards finding novel solutions and their implementation.

The dialogue featured:
・Per Wahlstedt – Expert, Health and Cancer Care, Swedish Cancer Society (Chair)
・Lesley Ogilvie – Director, Global AMR R&D Hub
・Henry Skinner – Chief Executive Officer, AMR Action Fund
・Margo Warren– Director of Government Engagement and Policy, Access to Medicine Foundation
・Gregory Frank – Director, Global Public Policy, MSD

Curious about more?

You can sign up for our newsletter here. By subscribing, you automatically provide your consent for the use of your data in accordance with our privacy policy.

This field is for validation purposes and should be left unchanged.

Latest news

Go to all news
Dynamic Dashboard